Skip to main content Back to Top
Advertisement

VTE Prophylaxis in the Medically Ill: Extending the Conversation, Part 2

Broadcast Date: April 29, 2021

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Pharmacists have a role in managing anticoagulant therapy in acutely ill hospitalized patients at risk for VTE, including protocol development and research, identifying unmet need and the value of prophylaxis in medically ill patients, and implementing practical DVT and PE prevention strategies. Consensus guidelines (e.g., COVID-19 ISTH 2020, COVID-19 ACC) have provided some guidance for COVID-19 infection and the connection to deep vein thrombosis and pulmonary embolism.

SPEAKERS

John FanikosJohn Fanikos, R.Ph., M.B.A., is Chief of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. Mr. Fanikos is responsible for the overall Pharmacy Department operations. As part of his research interests, he has worked closely with the BWH Thromboembolism Research Group for over 25 years. He has authored and co-authored over 100 peer reviewed articles and textbook chapters on medication use with a specific emphasis on optimizing medication utilization. His research focus has been identifying and avoiding the problems and pitfalls of medication use.

Relevant Financial Relationship Disclosure with an Ineligible Company*

  • Consultant, Pfizer
  • Consultant, Pacira
  • Consultant, Boehringer-Ingelheim
  • Consultant, Allergan
  • Consultant, Alexion

All of the relevant financial relationships have been mitigated.
*As defined by the Standards of Integrity and Independence definition of ineligible company.

Arthur AllenArthur Allen is a Clinical Pharmacy Specialist and the Anticoagulation Program Manager for the VA Salt Lake City Health Care System in Salt Lake City, Utah. He has nearly 20 years of anticoagulation and thrombosis experience and serves on the Board of Directors for the Anticoagulation Forum.

Relevant Financial Relationship Disclosure with an Ineligible Company*

  • Speaker’s Bureau, Janssen Pharmaceuticals
  • Advisory Board, BMS/Pfizer Alliance
  • Speaker’s Bureau, Alexion/Portola Pharmaceuticals

All of the relevant financial relationships have been mitigated.
*As defined by the Standards of Integrity and Independence definition of ineligible company.

 

This podcast is provided by ASHP and sponsored by Janssen Pharmaceuticals, Inc.

 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.